Driven by Science.
Focused on Patient Impact.

Corporate Presentation

KAIROS DISCOVERY

Headquarters
36 rue Jeanne d'Arc
69003 Lyon, France
(+33).621.86.43.87
www.kairos-discovery.com
a.bancet@kairos-discovery.com

Overcoming Resistance in Hard-to-Treat Cancers

Nearly **2 of 3 cancers**‡ are driven by dysregulated kinase activity, proteins that sustain tumor growth and therapeutic resistance.

Founded in 2022 (Lyon, France), Kairos develops next-generation treatments targeting underexploited kinases, with a business model built for pharma partnering, accelerating the translation of new options to patients.

€2 M+

secured to date, supported by multiple innovation awards.

i-PhD i-Lab concours d'innovation TechTour CLARA CANCÉROPÔLE LYON AUVERGNE RHÔNE-ALPES

Meet the Kairosians

Rooted in Science. Reaching for Patients.

Multidisciplinary team combining youthful energy and scientific expertise, backed by experienced advisors and a committed board → COO hire planned (Q3 2026).

Management



Alexandre BANCET
CEO & CSO, Board Member
Ph.D. Medicinal Chemistry
Management & Business



David NEVES
CTO
+20y Oncology R&D — From discovery to clinic

Non-Clinical Team



Gabriela MAKULYTE
Preclinical Project Manager
Ph.D. Molecular & Cell Biology
Tumor Models



Alexandre ARNAUD
Chemistry & Quality
M.Sc. Medicinal Chemistry
Analytics & Early CMC



Léna MARLHOUX
Ph.D. Fellow
M.Sc. Molecular & Cell Biology
Mechanism of Action

Scientific Advisors



Isabelle KRIMM
Drug Discovery Advisor
Ph.D. Structural Biology — **Scientific Founder**



Gabriel ICHIM
Oncology Advisor
Ph.D. INSERM Research Director — Cell Death & Oncology

Board of Directors



Jean-Guillaume LAFAY
Chairman of the Board
Operating Partner — Former CEO, Mablink Bioscience (acquired)



Philippe ARCHINARD
Board Member
Ph.D., Executive VP, Institut Mérieux — Former CEO, Transgene



Émilie RICHARD
Board Member
Investment Director, UI — Seed-stage Venture Capital




Jean-Marie GRUMEL
Board Member
M.D., 40y Pharma Industry — Business Angels Network




Stéphane LEGASTELOIS
Board Member
Ph.D., Serial Entrepreneur — Investment Director

Building a Differentiated Oncology Pipeline

Kairos develops next-generation small-molecule therapeutics, led by a selective CK2 inhibitor demonstrating strong preclinical efficacy and early pharmaceutical interest.



Delivering novel treatments by targeting underexploited kinases with differentiated mechanisms of action.



Competitor landscape

Targeting the Kinase CK2 in Cancer


CK2 is a master regulator of tumor cell survival, therapy resistance, and immune evasion. It is consistently overexpressed across a wide range of solid and hematologic malignancies.[‡] Despite strong biological rationale, no meaningful clinical success has been achieved to date.

AstraZeneca · APOLLO THERAPEUTICS · Bristol Myers Squibb™ · Senhwa BIOSCIENCES

Selected companies with CK2-targeting programs


Current approaches **lack precision** and fail **to fully inhibit** CK2, limiting dosing and allowing tumor survival mechanisms to persist.

Reengineering CK2 Inhibition for True Selectivity



Non-Selective Profile

By targeting only the ATP-pocket, first-generation CK2 inhibitors such as **silmitasertib** showed limited clinical benefit in part due to poor selectivity and off-target toxicity.



Highly-Selective Profile


Our bivalent approach engages both the ATP pocket and the CK2-specific αD pocket, achieving high selectivity and sustained inhibition.


CK2: High Potential. Historically Underexploited

Silmitasertib — Proteomic Signature
24 h treatment at IC_{50} in 786-O cells (vs. control)

- Autophagy / Proteostasis
- Death Receptor Signaling
- Amino Acid Metabolism
- Translational Suppression
- Immunity / Vesicular Traffic
- Cell Cycle Progression

Bivalent CK2 Inhibitor — Proteomic Signature
24 h treatment at IC_{50} in 786-O cells (vs. control)





Incomplete Pathway Suppression

First-generation CK2 inhibitors failed to fully block the survival signals that help tumors resist treatment — which limited their long-term effectiveness.


Broader Tumor Impact

Dual-site blockade drives deeper antitumor responses — not only halting tumor growth, but also activating immune and stress-response pathways within the tumor.


Bivalent Precision. Deep Tumor Impact

Bivalent CK2 inhibitors (CK2bi.), unlike silmitasertib, trigger a multifactorial cell death program, including caspase-independent pathways, to overcome tumor resistance.

FACS analysis, 72h IC_{50} treatment in 786-O cells (vs. control).




Cell death analysis, 72h treatment in 786-O cells, ± caspase-3/7 KO (left) or pan-caspase inhibition (right).





Outperforms First-generation CK2 inhibitors *In Vivo* with Sustained Target Engagement

Antitumor efficacy in a 786-O renal cancer xenograft model (n = 8/group, mean ± SEM).



Pharmacodynamic analysis confirms apoptosis induction (e.g. cleaved-Casp8), on-target engagement, and substrate (e.g. AKT, p21) modulation in tumors.







Robust Efficacy in Selected Indications

Strong antitumor activity in colorectal (CRC) and renal (ccRCC) cancer models, further enhanced in combination.


Monotherapy Tumor Control



Improved Efficacy of First- and Second-line Therapies




With Favorable Tolerability Profile




KDX-350, Our Optimized Candidate

Large-scale pharmacology screen demonstrating broad KDX350 activity across adult, pediatric and histologically diverse cancers.



Parameters	KDX-350
Mechanism of Action	Bivalent CK2 inhibitor (ATP + αD pocket)
Biochemical Potency	IC_{50} = 9 nM, K_D = 23 nM
Cellular potency	Broad anti-tumor activity (IC_{50} 0.3-3 µM)
In Vivo Efficacy	Robust TGI (60–100%) in CRC and RCC models
Oral Bioavailability	Orally active with dose-dependent systemic exposure (30–300 mg/kg)
ADME/PK	Moderate human hepatocyte clearance; no major reactive metabolites; low CYP-mediated DDI risk

Induction of cell death in tumor tissues (e.g. colorectal carcinoma model)



KDX-350 delivers strong oral exposure, favorable tolerability, and robust antitumor activity *in vivo*, supported by broad *in vitro* activity across >590 cancer models and defined molecular determinants of response.

Securing Long-Term Value Through IP

The program is protected by two complementary patent families covering the chemical series, with no third-party IP identified as blocking the core structure, mechanism of action, or therapeutic combinations.

2 Patent Families

Family 1 — Indole derivatives for cancer treatment

Exclusive license from the University of Lyon (France)

National phase filings across Europe, North America and Asia since 2023



Family 2 — Substituted azaindoles for cancer treatment

Fully owned by Kairos Discovery

PCT filing (mid-2026), with global expansion planned in 2027

2040+ Patent protection

Market potential

Combination-ready asset with broad applicability across multiple oncology indications.

Scalable Manufacturing

Synthesis and formulation suitable for clinical-scale GMP.

IP strategy and FTO studies managed with Becker & Associés (Top-ranked patent firm, Leaders League)

2026 | ‡European patent protection including AT, BE, BG, DE, DK, EE, ES, FI, FR, IE, IT, LT, LU, LV, MT, NL, PT, RO, SE, SI

Targeted Kinase Market : A Multi-Billion Dollar Opportunity

~100 kinase inhibitors approved over the past 20 years, with global sales projected to exceed $90B by 2029, driven by a 7–9% CAGR.

Kairos develops targeted cancer therapies in a fast-growing market attracting major pharma players, with strong partnering and acquisition potential.

Our Model — Revenue Strategy

Out-licensing strategy with pharmaceutical partners for clinical development and commercialization.
$2.5–25M upfront, up to $200M+ in clinical milestones, 8–15% royalties on net sales.


Company Development

Reinvest partnership revenues to expand the pipeline, advance a second program, and create long-term value for shareholders.

Significant value inflection post-licensing, with milestones representing up to

10–100x

the upfront payment



Positioning Kairos for a future M&A exit

Recent Acquisition in our Field

Lilly + SCORPION

STX-478 (PI3Kα inhibitor)
~$2.5B

Takeda + nimbus THERAPEUTICS

TAK-279 (TYK2 inhibitor)
$4B upfront + $2B mil.

Licensing Deal Benchmarks


Positioning Kairos for a first strategic licensing transaction by mid-2027 for its lead asset, KDX-350, supported by early formalized interest from a leading pharmaceutical company.

Company	Acquirer	Target, Program	Stage	Upfront	Milestones, Royalties	Date
Repare Therapeutics	Debiopharm	PKMYT1, kinase inhibitor	Phase I	$10 M	Up to $250 M + single-digit royalties	2025
Kymera Therapeutics	GILEAD	CDK2, targeted protein degrader	Preclinical	Up to $85 M (option and early milestones)	Up to $750 M + tiered royalties	2025
Aqilion	MERCK	TAK1, kinase inhibitor	Preclinical	€10 M	Up to €950 M + tiered royalties	2023
Usynova Pharmaceuticals	AstraZeneca	$KRASG^{12D}$, RAS pathway inhibitor	Preclinical	$24 M	Up to $395 M + royalties	2023
Redx Pharma	Jazz Pharmaceuticals	RAF, kinase inhibitor	Preclinical	$3.5 M	Up to $203 M + royalties	2019

Selected licensing deals in our field (including kinase inhibitors and CK2-adjacent programs) highlight the value of early-stage transactions in targeted oncology — offering a rare opportunity for meaningful returns prior to clinical entry.


Milestones to First Strategic Partnership

This round delivers a pharma-aligned preclinical data package, positioning KDX-350 for a strategic licensing opportunity by 2027. If no deal is secured, the program will progress through GLP toxicology and into first-in-human studies, representing the next key value inflection point, supported by a Series A financing.



The vast majority of funding will be allocated to KDX-350, with a small portion dedicated to initiating preclinical PoC studies on a second program (cyclin/CDK complex degrader),[‡] based on promising early data.

€1.5 M Raise to Reach Licensing Readiness (16-Month Runway)



Use of funds

Peak burn during execution phase, stabilizing to €40–45k/month

Category	Details	Amount (€)
Preclinical Activities (Outsourced)	Pharmacology studies, DMPK (non-GLP), CMC & formulation	420,000
Human Resources	Existing team + COO hire	420,000
G&A & Operations	Infrastructure & support services (legal, accounting, insurance, IT)	310,000
Debt Repayment	Bank financing repayment	185,000
Internal R&D	Medicinal chemistry & in-house pharmacology	110,000
Intellectual Property Strategy	Patent maintenance & freedom-to-operate analyses	22,000
	Total	**1,467,000 €**

Seed Extension Round
€1.5 M Target
Closing Q3 2026

€0.85 M+ Equity Financing

- Syndication discussions ongoing with major family offices, alongside a regional investment fund that has expressed its investment intention.
- Historical business angels and existing shareholders supporting the round.
- Capital Cell campaign with oversubscription capacity.

€0.2 M Debt

Bank financing secured post-closing, provided by a historical banking partner in syndication.

€0.5 M+ Non-Dilutive Funding

- Bpifrance funding secured, with disbursements linked to program milestones.
- ~€150k Research Tax Credit (CIR) expected in 2027.

Why Invest Now ?
Partner-Ready Asset by 2027

Proven Team & Execution
Operational and advisory team with hands-on experience across drug discovery, clinical development and pharma partnering.

Validated Science & Strong IP
Independently validated efficacy data,[‡] favorable tolerability profile and a worldwide patent estate.

First Pharma Traction & Attractive Entry Point
LOI received from an pharmaceutical company, supporting a potential licensing deal by mid-2027, with an estimated exit valuation exceeding 200 M€ by 2030.[#]

€2.8 M
pre-money valorisation

Up to 20x
return for current investors

From Molecule to Mission
Building the Future of Oncology Together

Join us !

KAIROS DISCOVERY



Alexandre BANCET
Co-founder, CEO
(+33).621.86.43.87
a.bancet@kairos-discovery.com
www.kairos-discovery.com